Myelosuppression associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF nurse leadership board

Clinical Journal of Oncology Nursing

Volumn 12, Issue SUPPL. 3, 2008, Pages 13-19

  Miceli, Teresa ^a   Colson, Kathleen ^b   Gavino, Maria ^c   Lilleby, Kathy ^d  

^a Rochester Medical Center   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD CELL COUNT; BONE MARROW; CONSENSUS; DRUG EFFECT; HUMAN; LEADERSHIP; MULTIPLE MYELOMA; NURSING ORGANIZATION;

ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BONE MARROW; CONSENSUS; HUMANS; LEADERSHIP; MULTIPLE MYELOMA; SOCIETIES, NURSING;

EID: 49649089487     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08     Document Type: Article

References (39)

1. American Association of Blood Banks, America's Blood Centers, & American Red Cross. (2006). Circular of information for the use of human blood and blood components. Retrieved September 10, 2007, from http://www.aabb.org/Documents/About_Blood/Circulars_of_Information/coiwnv0702.pdf
2. Amgen Inc. (2007a). Aranesp® (darbepoeitin alfa) [Package insert]. Thousand Oaks, CA: Author.
3. Amgen Inc. (2007b). Epogen® (epoeitin alfa) [Package insert]. Thousand Oaks, CA: Author.
4. Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2007). Nursing guidelines for enhanced patient care. Haematologica, 92(Suppl. 2), 211.
5. Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2008). Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 9-12.
6. Boyer, C.G. (2000). Chemotherapy-related anemia and fatigue in home care patients: A home care nurse's guide to recognition, assessment, and intervention. Home Healthcare Nurse, 18(4, Suppl.), 3-15.
7. Burney, K.Y. (2000). Tips for timely management of febrile neutropenia. Oncology Nursing Forum, 27(4), 617-618.
8. Cable, R., Carlson, B., Chambers, L., Kolins, J., Murphy, S., Tilzer, L., et al. (2002). Practice guidelines for blood transfusion: A compilation from recent peer-reviewed literature. Retrieved September 10, 2007, from http://www.redcross.org/services/biomed/profess/pgbtscreen.pdf
9. Celgene Corporation. (2007a). Revlimid® (lenalidomide) [Package insert]. Summit, NJ: Author.
10. Celgene Corporation. (2007b). Thalomid® (thalidomide) [Package insert]. Summit, NJ: Author.
11. Centers for Disease Control and Prevention. (1996). Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 45(RR11), 1-25.
12. Cleeland, C.S., & Wang, X.S. (1999). Measuring and understanding fatigue. Oncology, 13(11A), 91-97.
13. Fortner, B.V., Houts, A.C., & Schwartzberg, L.S. (2006). A prospective investigation of chemotherapy-induced neutropenia and quality of life. Journal of Supportive Oncology, 4(9), 472-478.
14. Fortner, B.V., Tauer, K., Zhu, L., Ma, L., & Schwartzberg, L.S. (2004). The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: A national survey. Community Oncology, 1(4), 211-217.
15. Foubert, J. (2006). Cancer-related anaemia and fatigue: Assessment and treatment. Nursing Standard, 20(36), 50-57.
16. Fukuyama, S.N., & Itano, J. (1999). Thrombocytopenia secondary to myelosuppression. American Journal of Nursing, April(Suppl.), 5-12.
17. Ghobrial, J., Ghobrial, I.M., Mitsiades, C., Leleu, X., Hatjiharissi, E., Moreau, A.S., et al. (2007). Novel therapeutic avenues in myeloma: Changing the treatment paradigm. Oncology, 21(7), 785-792.
18. Held-Warmkessel, J. (1998). Chemotherapy complications. Nursing, 28(4), 41-46.
19. Held-Warmkessel, J. (2000). Assessment of febrile neutropenic patients. Clinical Journal of Oncology Nursing, 4(4), 182-184.
20. Khorana, A.A., Francis, C.W., Culakova, E., Fisher, R.I., Kuderer, N.M., & Lyman, G.H. (2006). Thromboembolism in hospitalized neutropenic cancer patients. Journal of Clinical Oncology, 24(3), 484-490.
21. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., et al. (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78(1), 21-33.
22. Lonial, S., Richardson, P.G., San Miguel, J., Sonneveld, P., Schuster, M., Blade, J., et al. (2007). Hematologic profiles with bortezomib in relapsed MM [Abstract PO-622]. Haematologica, 92(Suppl. 2), 159-160. Retrieved April 10, 2008, from http://www.haematologica.it/content/vol92/6_supplement_2/index.dtl
23. Lonial, S., Waller, E.K., Richardson, P.G., Jagannath, S., Orlowski, R.Z., Giver, C.R., et al. (2005). Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 106, 3777-3784.
24. Manochakian, R., Miller, K., & Chanan-Khan, A.A. (2007). Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist, 12(8), 978-990.
25. Marrs, J.A. (2006). Care of patients with neutropenia. Clinical Journal of Oncology Nursing, 10(2), 164-166.
26. Millennium Pharmaceuticals, Inc. (2006). Velcade® (bortezomib) [Package insert]. Cambridge, MA: Author.
27. National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events v.3.0. Retrieved December 28, 2007, from http://ctep.cancer.gov/forms/CTCAEv3.pdf
28. National Cancer Institute. (2007). Dictionary of cancer terms. Retrieved December 28, 2007, from http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44173
29. Nunez, A.M., & Liebman, M.C. (1999). Febrile neutropenia. American Journal of Nursing, 99(Suppl.), 9-12, 34-36.
30. Pandit, S.R., & Vesole, D.H. (2003). Management of renal dysfunction in multiple myeloma. Current Treatment Options in Oncology, 4(3), 239-246.
31. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106(13), 4050-4053.
32. Richardson, P.G., & Anderson, K. (2006). Thalidomide and dexamethasone: A new standard of care for initial therapy in multiple myeloma. Journal of Clinical Oncology, 24(3), 334-336.
33. Richardson, P.G., Hideshima, T., Mitsiades, C., & Anderson, K.C. (2007). The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network, 5(2), 149-162.
34. Rome, S., Doss, D., Miller, K., Westphal, J., & the IMF Nurse Leadership Board. (2008). Thromboembolic events associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 21-27.
35. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., et al. (2006). 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. Journal of Clinical Oncology, 24(19), 3187-3205.
36. Spivak, J.L. (1994). Recombinant human erythropoietin and the anemia of cancer. Blood, 84(4), 997-1004.
37. Turgeon-Lanes, P., & Randolph, S. (2000). Home care management of febrile neutropenia: Creating a pilot program. Home Health Care Consultant. 7(1), 1A-6A.
38. West, F., & Mitchell, S.A. (2004). Evidence-based guidelines for the management of neutropenia following outpatient hematopoietic stem cell transplantation. Clinical Journal of Oncology Nursing, 8(6), 601-613.
39. Zitella, L., Friese, C., Gobel, B.H., Woolery-Antill, M., O'Leary, C., Houser, J., et al. (2006). Putting Evidence Into Practice®: Prevention of infection. Retrieved September 10, 2007, from http://www.ons.org/outcomes/volume1/prevention.shtml1